Molecular Metabolism in Treatment of High Altitude Polycythemia with Duoxuekang Capsule
Molecular Metabolism in Treatment of High Altitude Polycythemia with Duoxuekang Capsule
Jia Nie1*, Ze Weng Yong Zhong1, Di Wang2 and Ming Jian Li3
Effect of different concentration of duoxuekang on pathological characteristics of lung of rats suffering from high altitude polycythemia (×400). A, N: Plain control; B, M: high altitude model group; C, C: Nusdikand drug group; D, DXKH: high dose duoxuekang group; E, DXkM: middle dose duoxuekang group; F, low dose duoxuekang group.
Pathological examination of cardiac slices of rats in each group (×400). A, N: Plain control; B, M: high altitude model group; C, C: Nusdikand drug group; D, DXKH: high dose duoxuekang group; E, DXkM: middle dose duoxuekang group; F, low dose duoxuekang group.
PCA analysis of HAPC model.
Potential serum differential metabolites of Duoxuekang capsule in the treatment of HAPC.
Pathway analysis of M, DXKH and DXKL groups rats.
